Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$1.12
EPS est.
$0.92
EPS surprise
+22.00%
1-day move
-4.65%
Globus Medical reported better-than-expected earnings per share, surpassing analyst estimates by 22%. However, the stock fell by 4.65% on the day, indicating that investors may have been disappointed by the lack of revenue information and guidance. The absence of a management commentary could also contribute to uncertainty among investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.12 | $0.92 | +22.00% |
| Revenue | — | $741M | — |
No transcript is on record, and the analysis is based solely on numerical results.
Globus Medical, Inc. (GMED) is a leading medical device company focused on developing innovative solutions for spinal surgery. Operating in the Health Care Equipment sector, it plays a crucial role in improving patient outcomes through advanced technology and surgical techniques.
Last quarter
In Q4-2025, Globus Medical reported an EPS of $1.28, significantly exceeding estimates by 20.41%. However, the stock saw a slight decline of 1.63% the following day.
Management promises and guidance
EPS beat streak
5Q
EPS beat rate
88%
Avg EPS surprise
+16.59%
Avg 1-day reaction
-0.05%
Analysts expect a solid performance from Globus Medical in Q1-2026, with a consensus EPS of $0.92 and revenue of $741M. The market is closely watching how the company will navigate potential challenges in the health care sector.
Bull case
If the company can exceed EPS expectations and show strong revenue growth, it could signal robust demand for its products and lead to a positive market reaction.
Bear case
Conversely, if the company misses its EPS or revenue targets, it may raise concerns about its growth trajectory and competitive positioning, potentially leading to a negative stock reaction.
Key metrics to watch
EPS
$0.92Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.
Revenue
$741MRevenue growth reflects the company's ability to expand its market presence and drive sales, which is vital for long-term success.
The print will turn on these.
Q1
Will EPS exceed the consensus estimate of $0.92?
A beat on EPS would reinforce investor confidence in the company's profitability and operational efficiency.
Q2
What are the revenue expectations in light of market conditions?
Revenue performance is crucial for assessing the company's growth potential and market demand for its products.
—
Est. EPS
$0.11
Est. Rev
$326M
Impl. Move
±7.3%
Why consensus could be wrong
The consensus may underestimate the company's ability to capitalize on recent innovations in spinal surgery, leading to stronger-than-expected revenue growth.
Supporting evidence
Recent earnings history shows a consistent ability to beat EPS estimates, suggesting potential for another surprise.
The options market indicates a larger expected move than historical averages, hinting at possible positive sentiment.
Management's previous commitments to innovation may not be fully reflected in current estimates.
Key risk
If revenue growth exceeds $785M, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it will provide insights into the company's ability to sustain growth amidst competitive pressures.
Bull confirmed if
An EPS of $1.06 or higher would confirm strong operational performance and market demand.
Bear confirmed if
An EPS below $0.80 would signal potential weaknesses in profitability and market challenges.
What the market is pricing for the move.
Implied Move
±8.7%
Historical Avg
±1.35%
The options market is pricing in a significant move of approximately 8.7% around the earnings report, suggesting heightened volatility expectations.
Options are pricing a larger move than the historical average, indicating that traders expect more volatility than usual.
ATM IV
1.1%
30d HV
33.3%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: X of Y (Z%)
This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 3.3%, with a raw directional average of +2.1% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
92.23%
of float
Insider
0.61%
of float
Holders
788
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
10,806,724 sh · $797.0M
8.05%
2.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If GMED beats expectations, history suggests the stock could rise by approximately 0.89%, confirming strong demand and operational efficiency.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
A miss could lead to a decline of about 1.33%, raising concerns about the company's growth trajectory.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
1 buy·0 sells
Members
1
House only
Est. Notional
$15,001.00–$50,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Jupiter Topco LLC
8,200,423 sh · $604.8M
6.11%
100.0%
Vanguard Capital Management LLC
5,107,532 sh · $376.7M
3.80%
1.5%
Vanguard Portfolio Management LLC
4,994,385 sh · $368.3M
3.72%
2.4%
Invesco Ltd.
4,309,771 sh · $317.8M
3.21%
-0.2%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net buying
Recent Transactions
Traded Aug 19, 2026 · disclosed Sep 10, 2026
$15,001.00–$50,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.